Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-05-27 13:49 CEST (UTC+2h)

endogenous compounds [Regulatives / Guidelines]

posted by martin - Austria, 2017-05-08 19:50  - Posting: # 17322
Views: 593

Dear all,

I would like to open again a new thread regarding endogenous compounds in BE assessments.

Simple case:

- assuming no circadian rhythm / temporarily constant
- baseline subtraction method (e.g. median of at several pre-dose samples)

Several guidelines mention that a negative pre-dose corrected value should be set to zero. However, what about subsequent levels?

I think setting also all concentrations after the first negative to zero would make some sense as otherwise we just have “noise” in the AUC (i.e. increase variability) and it’s rather impossible to get a reliable estimate for lambda_z (for calculation of AUC0-inf). I think this should be also in-line with guidelines as the method for baseline subtraction needs to be specified a-priori.

Best regards and looking forward to thoughts from more experienced members in this forum


PS.: premise of stable endogenous could be verified by looking at adjusted concentrations after the first negative (inclusive) adjusted concentration: should be symmetrically distributed around zero.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
16,926 Posts in 3,626 Threads, 1,030 registered users;
20 users online (0 registered, 20 guests).

EMEA. The European Medicines Evaluation Agency.
The drug regulatory agency of the European Union.
A statistician-free zone.    Stephen Senn

BEBAC Ing. Helmut Schütz